Alemtuzumab

Alemtuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from rat)
Target	CD52
Clinical data
Trade names	Campath, Mabcampath, Lemtrada, others
AHFS/Drugs.com	Monograph
MedlinePlus	a608053
License data	US DailyMed: Alemtuzumab;
Pregnancy; category	AU: B3(Lemtrada); B2 (Mabcampath);
Routes of; administration	Intravenous infusion
ATC code	L04AG06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	~288 hrs
Identifiers
CAS Number	216503-57-0 ;
DrugBank	DB00087 ;
ChemSpider	none;
UNII	3A189DH42V;
KEGG	D02802;
ChEMBL	ChEMBL1201587 ;
Chemical and physical data
Formula	C6468H10066N1732O2005S40
Molar mass	145454.20 g·mol−1
	(what is this?) (verify)

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.

It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.

Alemtuzumab was approved for medical use in the United States in 2001. (Mab)Campath was withdrawn from the markets in the US and the EU in 2012, to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.